Core Viewpoint - Chengdu Olin Biotechnology Co., Ltd. has signed a strategic cooperation framework agreement with Jiangsu Provincial Center for Disease Control and Prevention, focusing on vaccine research and development, disease prevention, and public health capacity building [1] Group 1: Strategic Focus Areas - The collaboration will concentrate on three core areas: vaccine research and development, disease prevention, and public health capacity building [1] - The partnership aims to promote scientific research innovation, talent reserve, integration of medical prevention, and coordinated health services development [1] Group 2: Specific Initiatives - Key initiatives include advancing innovative vaccine clinical research and evaluation [1] - The agreement also emphasizes optimizing adult vaccination service systems and upgrading regional infectious disease prevention technologies [1]

Core Viewpoint - Oulin Biotech has shown significant stock performance with a year-to-date increase of 169.43%, despite a recent slight decline in the last five trading days [1] Group 1: Stock Performance - As of September 9, Oulin Biotech's stock price reached 28.56 CNY per share, with a market capitalization of 11.593 billion CNY [1] - The stock has experienced a 1.07% decline over the last five trading days, but a 39.32% increase over the last 20 days and a 76.62% increase over the last 60 days [1] - The company has appeared on the "龙虎榜" (top trading list) twice this year, with the latest occurrence on August 20 [1] Group 2: Financial Performance - For the first half of 2025, Oulin Biotech reported a revenue of 306 million CNY, representing a year-on-year growth of 35.17% [2] - The net profit attributable to shareholders for the same period was 13.197 million CNY, showing a substantial increase of 147.22% year-on-year [2] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased by 4.86% to 6,521, while the average number of circulating shares per person decreased by 4.63% to 62,169 shares [2] - The company has distributed a total of 15.434 million CNY in dividends since its A-share listing [3] - Among the top ten circulating shareholders, "兴全合润混合A" holds 15.4402 million shares, while "兴全合宜混合A" holds 8.9214 million shares, with both maintaining their holdings from the previous period [3]

Group 1 - The company, Olin Bio, announced its participation in the 2025 semi-annual performance briefing for the innovative drug industry on September 16, 2025, from 15:00 to 17:00 [2]

证券代码：688319 证券简称：欧林生物 公告编号：2025-046 成都欧林生物科技股份有限公司关于参加 2025 年半 年度科创板创新药行业集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 09 月 09 日(星期二)至 09 月 15 日(星期一)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@olymvax.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 成都欧林生物科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度的经营成果、财务状况，公司计划于 2025 年 09 月 16 日(星期二)下午 15:00-17:00 参加 2025 年半年度科创板创新药行业集体业绩说明会，就投资者 关心的问题进行交流。 一、说明会类型 会议召开时间：2025 年 09 月 16 日(星期二)下午 15:0 ...

Summary of Key Points Core Viewpoint - The recent block trades of Olin Bio indicate a significant discount relative to the market price, suggesting potential investor interest at lower valuations [1][2]. Trading Activity - On September 5, Olin Bio recorded two block trades totaling 279,000 shares, with a transaction value of 7.0196 million yuan, at a price of 25.16 yuan per share, reflecting a 10.14% discount compared to the closing price [1]. - Over the past three months, Olin Bio has seen a total of four block trades with a cumulative transaction value of 17.6099 million yuan [2]. Market Performance - The closing price of Olin Bio on the same day was 28.00 yuan, marking a 2.38% increase, with a daily turnover rate of 2.24% and a total trading volume of 250 million yuan [2]. - The stock has experienced a decline of 5.98% over the past five days, with a net outflow of funds amounting to 31.7818 million yuan during this period [2]. Margin Trading - The latest margin financing balance for Olin Bio stands at 294 million yuan, having increased by 81.5122 million yuan, which represents a growth of 38.34% over the last five days [2].

Group 1 - On September 5, 2025, Olin Bio conducted a block trade of 279,000 shares, with a transaction amount of 7.0196 million yuan, accounting for 2.73% of the total transaction volume for the day [1] - The transaction price was 25.16 yuan, representing a discount of 10.14% compared to the market closing price of 28 yuan [1] - The block trade involved multiple brokerage firms, including Guotou Securities and CITIC Securities, indicating a diversified trading interest [2]

Core Points - Olin Bio announced that as of the disclosure date, the financial officer and vice president, Mr. Tan Yong, holds 571,440 shares, accounting for 0.14% of the total share capital [1] - The company’s secretary of the board and vice president, Mr. Wu Wei, holds 778,400 shares, representing 0.19% of the total share capital [1] - Both executives plan to reduce their holdings through centralized bidding, with Mr. Tan Yong intending to sell up to 128,860 shares and Mr. Wu Wei up to 178,500 shares within three months after the announcement, starting 15 trading days from the disclosure [1]

Core Viewpoint - The announcement details the share reduction plans of senior management personnel at Chengdu Olin Biological Technology Co., Ltd., specifically financial officer Tan Yong and secretary of the board Wu Wei, who plan to reduce their holdings for personal financial planning reasons [3][12]. Summary by Sections Senior Management Shareholding Overview - As of the announcement date, financial officer Tan Yong holds 571,440 shares, representing 0.14% of the total share capital, with 515,440 shares being tradable and 56,000 shares being restricted [2]. - Secretary of the board Wu Wei holds 778,400 shares, accounting for 0.19% of the total share capital, with 714,000 shares being tradable and 64,400 shares being restricted [2]. Details of the Reduction Plan - Tan Yong and Wu Wei plan to reduce their holdings by up to 128,860 shares and 178,500 shares, respectively, through centralized bidding within three months after the announcement [3][12]. - The number of shares to be reduced will be adjusted if any corporate actions such as dividends or stock splits occur during the reduction period [3]. - Both individuals are compliant with regulations regarding share reductions and do not fall under any prohibitive conditions [3][12]. Background of the Reducing Parties - The reducing parties do not have any concerted actions with other shareholders [4]. - Neither Tan Yong nor Wu Wei has reduced their holdings since the company went public [5]. Commitments and Regulations - Tan Yong and Wu Wei have made commitments regarding their shareholding, including not transferring shares within 12 months of the company's listing and adhering to specific conditions if the company has not achieved profitability [7][8]. - They are also bound by regulations that limit the amount of shares they can sell within certain time frames and under specific conditions [8][9].

Core Viewpoint - Senior management personnel of Chengdu Olin Biological Technology Co., Ltd. plan to reduce their shareholdings due to personal financial needs, with specific limits on the number of shares to be sold and the timeframe for the reduction [1][2][3]. Summary by Relevant Sections 1. Basic Information of Senior Management Shareholdings - As of the announcement date, the financial officer and deputy general manager, Mr. Tan Yong, holds 571,440 shares, accounting for 0.14% of the company, with 277,440 shares obtained before the IPO and 238,000 shares through other means [2]. - The company secretary and deputy general manager, Mr. Wu Wei, holds 778,400 shares, accounting for 0.19% of the company, with 204,000 shares obtained before the IPO and 510,000 shares through other means [2]. 2. Details of the Reduction Plan - Mr. Tan plans to reduce his holdings by no more than 128,860 shares, representing up to 0.0317% of the total shares [2][3]. - Mr. Wu plans to reduce his holdings by no more than 178,500 shares, representing up to 0.0440% of the total shares [3]. - The reduction will occur through centralized bidding and block trading from September 26, 2025, to December 25, 2025 [3]. 3. Reasons for Reduction - The reduction is primarily due to personal financial needs of the senior management personnel [3]. 4. Compliance and Commitments - Both Mr. Tan and Mr. Wu have committed to not reducing their pre-IPO shares within a complete accounting year and have agreed to adhere to relevant regulations regarding share transfers [3][4].

Group 1 - The company, Olin Bio, announced that as of the disclosure date, its financial officer and deputy general manager, Mr. Tan Yong, holds approximately 570,000 shares, accounting for 0.14% of the total share capital [1] - Mr. Tan plans to reduce his holdings by up to approximately 128,900 shares, while the company’s board secretary and deputy general manager, Mr. Wu Wei, holds about 778,400 shares, representing 0.19% of the total share capital [1] - Mr. Wu also intends to reduce his holdings by up to approximately 178,500 shares within three months after the announcement of the reduction plan [1] Group 2 - For the year 2024, Olin Bio's revenue composition is primarily from the pharmaceutical manufacturing industry, which accounts for 99.53% of total revenue, with other businesses making up 0.47% [2] - The current market capitalization of Olin Bio is 11.1 billion yuan [3]